AbbVie Inc (ABBV)vsSensus Healthcare Inc (SRTS)
ABBV
AbbVie Inc
$217.72
+0.82%
HEALTHCARE · Cap: $368.38B
SRTS
Sensus Healthcare Inc
$3.09
-2.83%
HEALTHCARE · Cap: $46.92M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 228482% more annual revenue ($62.82B vs $27.48M). ABBV leads profitability with a 5.8% profit margin vs -28.1%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
SRTS
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.7%
Fair Value
$145.81
Current Price
$217.72
$71.91 premium
Margin of Safety
-6.3%
Fair Value
$4.48
Current Price
$3.09
$1.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Earnings expanding 433.3% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Revenue declined 62.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bull Case : SRTS
The strongest argument for SRTS centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 102.2x leaves little room for execution misses.
Bear Case : SRTS
The primary concerns for SRTS are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while SRTS is a turnaround play — different risk/reward profiles.
SRTS carries more volatility with a beta of 1.19 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 35/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sensus Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?